



Published in final edited form as:

Biochemistry. 2018 June 05; 57(22): 3126–3129. doi:10.1021/acs.biochem.7b01253.

## Stereospecific Formation of *Z*-Trisubstituted Double Bonds by the Successive Action of Ketoreductase and Dehydratase Domains from *trans*-AT Polyketide Synthases


Xinqiang Xie\* and David E. Cane\*

Department of Chemistry, Brown University, Box H, Providence, Rhode Island 02912-9108, United States

### Abstract

Incubation of ( $\pm$ )-2-methyl-3-ketobutyryl-SNAC (**3**) and ( $\pm$ )-2-methyl-3-ketopentanoyl-SNAC (**4**) with BonKR2 or OxaKR5, ketoreductase domains from the bongkreic acid (**1**) and oxazolomycin (**2**) polyketide synthases, in the presence of NADPH gave in each case the corresponding (*2R*, *3S*)-2-methyl-3-hydroxybutyryl-SNAC (**5**) or (*2R,3S*)-2-methyl-3-hydroxypentanoyl-SNAC (**6**) products, as established by chiral GC-MS analysis of the derived methyl esters. Identical results were obtained by BonKR2- and OxaKR5-catalyzed reduction of chemoenzymatically prepared (*2R*)-2-methyl-3-ketopentanoyl-EryACP6, (*2R*)-2-methyl-3-ketobutyryl-BonACP2 (**12**), and (*2R*)-2-methyl-3-ketopentanoyl-BonACP2 (**13**). The paired dehydratase domains, BonDH2 and OxaDH5, were then shown to catalyze the reversible *syn* dehydration of (*2R,3S*)-2-methyl-3-hydroxybutyryl-BonACP2 (**14**) to give the corresponding trisubstituted (*Z*)-2-methylbutenoyl-BonACP2 (**16**).

### Graphical abstract



Double bonds are ubiquitous structural features found in thousands of known bacterial polyketide natural products. While the vast majority are disubstituted or trisubstituted *E* double bonds, numerous polyketides harbor isomeric *Z* double bonds, such as those found in

\*Corresponding Authors: Xinqiang Xie, woshixinqiang@126.com. David E. Cane, david\_cane@brown.edu.

#### ORCID

David E. Cane: 0000-0002-1492-9529

Xinqiang Xie: 0000-0003-3943-7755

#### Notes

The authors declare no competing financial interest.

#### Supporting Information

Experimental methods, including sequence alignments, KR and DH design and expression, kinetic assays, and GC-MS and ESI-MS analysis of KR and DH incubations. This material is available free of charge on the ACS Publications website at DOI:10.1021/acs.biochem\*\*\*\*\*

bongkrelic acid (**1**)<sup>1</sup> and oxazolomycin A (**2**)<sup>2</sup> (Figure 1), as well as in fostriecin,<sup>3–5</sup> phoslactomycin,<sup>6</sup> borrellidin,<sup>7, 8</sup> bacillaene,<sup>9, 10</sup> curacin,<sup>11,12</sup> difficidin,<sup>13</sup> chivosazol A,<sup>14</sup> disorazol A,<sup>14</sup> lactimidomycin,<sup>14</sup> and macrolactin,<sup>14</sup> among many others. Modular polyketide synthases (PKSs) typically generate each double bond by the coupled action of a ketoreductase (KR) domain, which carries out the stereospecific, NADPH-dependent reduction of a 3-ketoacyl-acyl carrier protein (ACP) or a 2-methyl-3-ketoacyl-ACP chain elongation intermediate, and a paired dehydratase (DH) domain, which catalyzes the *syn* dehydration of the reduced 3-hydroxyacyl-ACP or 2-methyl-3-hydroxyacyl-ACP intermediate.

A variety of DH domains from modular PKSs have been expressed as discrete proteins and their reactions characterized biochemically. Thus EryDH4, from module 4 of the erythromycin PKS,<sup>15</sup> and NanDH2, from module 2 of the nanchangmycin PKS,<sup>16</sup> each catalyze the *syn* dehydration of a (2*R*,3*R*)-2-methyl-3-hydroxyacyl-ACP substrate to the corresponding trisubstituted (*E*)-2-methylenoyl-ACP. By contrast, RifDH10, from module 10 of the rifamycin PKS, catalyzes the analogous *syn* dehydration of the diastereomeric (2*S*, 3*S*)-2-methyl-3-hydroxyacyl-ACP to an (*E*)-2-methylenoyl-ACP product, in spite of the fact that the derived trisubstituted double bond in the ultimately formed rifamycin has the *Z* configuration, suggesting that the geometry must be altered subsequent to double bond formation.<sup>17</sup> PicDH2, from module 2 of the picromycin PKS,<sup>18, 19</sup> and FosKR1, from module 1 of the fostriecin PKS,<sup>5</sup> each catalyze the dehydration of a (3*R*)-3-hydroxyacyl-ACP substrate to the corresponding disubstituted (*E*)-2-enoyl-ACP. The predicted *syn* stereochemistry of the latter two dehydration reactions has yet to be confirmed experimentally. We recently reported that FosDH2, from module 2 of the fostriecin PKS, catalyzes the reversible dehydration of a (3*S*)-3-hydroxyacyl-ACP to the corresponding disubstituted (*Z*)-2-enoyl-ACP product.<sup>5</sup> This report was the first to document the in vitro DH-catalyzed formation of any (*Z*)-enoyl-thioester product. Indeed, for a variety of reasons, all prior attempts to demonstrate the predicted formation of disubstituted or trisubstituted (*Z*)-double bonds by recombinant PKS DH domains had been unsuccessful, resulting instead in the exclusive generation of the isomeric (*E*)-double bonds.<sup>7, 11, 12, 17, 20</sup>

We now report that BonDH2, from module 2 of the bongkrelic acid *trans*-AT PKS, and OxaDH5, from module 5 of the oxazolomycin *trans*-AT PKS (Figure 1), each catalyze the stereospecific *syn* dehydration of (2*R*,3*S*)-2-methyl-3-hydroxyacyl-ACP substrates, generated by the paired ketoreductases, BonKR2 and OxaKR5, respectively, to give the corresponding trisubstituted (*Z*)-2-methylenoyl-ACP products.

BonKR2 and BonDH2, from *Burkholderia gladioli* pathovar *cocovenenans*, and OxaKR5 and OxaDH5, from *Streptomyces albus*, were each expressed in *Escherichia coli* as *N*-terminal His<sub>6</sub>-tagged proteins using codon-optimized synthetic genes, based on consensus PKS domain boundaries (Figures S1–S4). Each of these four recombinant proteins was purified to homogeneity by immobilized Ni<sup>2+</sup> affinity chromatography. The purity and *M<sub>r</sub>* of each recombinant protein were assessed by SDS-PAGE and confirmed by LC-ESI(+)-MS analysis (Figure S5 and Table S1).

In common with the vast majority of polyketide synthase KR domains, all of which belong to the superfamily of short chain dehydrogenase/reductase (SDR) proteins,<sup>21, 22</sup> BonKR2 and OxaKR5 each harbor the highly conserved active site triad of Ser, Tyr, and Lys residues (Figure 2).<sup>23, 24</sup> On the other hand, both KR domains, along with other KR domains from *trans*-AT PKSs such as BaeKR9, from module 9 of the bacillaene PKS, and DifKR6, from module 6 of the difficidin PKS, lack the diagnostic sequence markers, such as the conserved Trp residue (A-Type KR domain) or Leu-Asp-Asp motif (B-Type KR domain), that are normally correlated with the respective (3*S*)- or (3*R*) configuration of the resultant 3-hydroxy acyl thioester reduction product (Figure 2).<sup>23–26</sup> Moreover, none of the additional conserved KR sequence features that are normally diagnostic of the (2*R*)- or (2*S*)-methyl configuration of the reduced 2-methyl-3-hydroxyacyl-thioester (KR subtypes 1 or 2) are evident in the amino acid sequences of these *trans*-AT KR domains. As a consequence, the intrinsic stereospecificity of BonKR2 or OxaKR5 cannot be deduced from simple consensus sequence alignments. (Although the Leu-Val-Asp triad of OxaKR5 might have suggested classification of OxaKR5 as a B-Type KR domain which would be predicted to generate a (3*R*)-3-hydroxyacyl group, the experiments described below establish firmly that OxaKR5 is an A1-Type KR.)

The reductase activities of BonKR2 and OxaKR5 were each confirmed and the steady-state kinetic parameters were determined using the model *N*-acetylcysteamine thioester substrates (±)-2-methyl-3-ketobutyryl-SNAC (**3**) and (±)-2-methyl-3-ketopentanoyl-SNAC (**4**)<sup>27</sup> and NADPH (Scheme 1a, Figures S6 and S7, Table S2). The stereochemistry of the resulting (2*R*,3*S*)-2-methyl-3-hydroxyacyl-SNAC products **5** and **6** was then established by chiral GC-MS analysis of the derived methyl esters **7-Me** and **8-Me**, including direct comparison with authentic synthetic standards of all four diastereomers of each product (Figures S8–S11, Tables S3 and S4).<sup>28</sup> We also used ACP-bound substrates to confirm the stereospecificity of the BonKR2- and OxaKR5-catalyzed reductions. Thus, in one set of experiments, (2*R*)-2-methyl-3-ketopentanoyl-EryACP6, generated by incubation of propionyl-SNAC with Ery[KS6][AT6], the ketosynthase-acyltransferase didomain from module 6 of the erythromycin PKS, and EryACP6 plus methylmalonyl-CoA,<sup>28</sup> was reduced in separate experiments with BonKR2 or OxaKR5 in the presence of NADPH to generate (2*R*,3*S*)-**9** (Scheme 1b). After basic hydrolysis and methylation with TMSCHN<sub>2</sub>, chiral GC-MS analysis confirmed the exclusive formation of methyl (2*R*,3*S*)-2-methyl-3-hydroxypentanoate (**8-Me**) (Figures S12 and S13, Table S3).

Finally, in a complementary series of incubations, a mixture of BonKS2, the ketosynthase from module 2 of the bongkreic acid PKS, and either acetyl-SNAC or propionyl-SNAC, was combined with malonyl-BonACP2, generated in situ as previously described by treatment of *apo*-BonACP2 with malonyl-CoA and the surfactin pantetheinyl transferase Sfp, so as to yield 3-ketobutyryl-BonACP2 (**10**) or 3-ketopentanoyl-BonACP2 (**11**) (Scheme 1c).<sup>29</sup> Stereospecific methylation of **10** or **11** was achieved as previously described<sup>29</sup> by treatment with a mixture of BonMT2, the *C*-methyl transferase from module 2 of the bongkreic acid PKS, and *S*-adenosyl methionine (SAM), in the presence of *S*-adenosylhomocysteine (SAH) nucleosidase to prevent potent product inhibition by the co-product SAH, yielding (2*R*)-2-methyl-3-ketobutyryl-BonACP2 (**12**) or (2*R*)-2-methyl-3-

ketopentanoyl-BonACP2 (**13**). In the presence of NADPH, incubation of **12** with either BonKR2 or OxaKR5 gave **14**, while reduction of **13** with BonKR2 gave **15**. Chiral GC-MS analysis of the derived methyl esters **7-Me** and **8-Me**, confirmed the exclusive formation of the corresponding (2*R*,3*S*)-2-methyl-3-hydroxybutyryl-BonACP2 (**14**) or (2*R*,3*S*)-2-methyl-3-hydroxypentanoyl-BonACP2 (**15**) (Figures S14–S16, Tables S3 and S4).

Having firmly established the stereochemistry of the BonKR2- and OxaKR5-catalyzed reductions, we next determined the stereospecificity of the paired dehydratase reactions. Chemoenzymatically prepared (2*R*,3*S*)-2-methyl-3-hydroxybutyryl-BonACP2 (**14**) was incubated in separate experiments with BonDH2 or OxaDH5 (Scheme 2a). Hydrolysis of the resultant acyl-ACP thioester (*Z*)-**16**, the product of *syn* dehydration, by treatment with PICS TE, the thioesterase from the picromycin PKS,<sup>30</sup> gave exclusively (*Z*)-2-methylbutenoic acid (**17**), as established by GC-MS analysis and direct comparison with authentic standards of both (*Z*)- and (*E*)-2-methylbutenoic acid (Figures S17 and S18). In a negative control, NigDH1, from module 1 of the nigericin PKS, did not dehydrate **14**.<sup>31</sup> (Although NigDH1 naturally acts only as a 2-methyl-3-ketobutyryl-ACP epimerase, we have shown that it also harbors a cryptic dehydratase activity capable of converting (2*R*,3*R*)-2-methyl-3-hydroxypentanoyl-ACP to (*E*)-2-methyl-2-pentenoyl-ACP.)<sup>31</sup> BonDH2 and OxaDH5 also catalyzed the reverse reaction, resulting in the stereospecific hydration of chemoenzymatically prepared (*Z*)-2-methylbutenoyl-BonACP2 (**16**) to yield exclusively the *syn* hydration product (2*R*,3*S*)-2-methyl-3-hydroxybutyryl-BonACP2 (**14**) (Scheme 2b). LC-ESI(+)-MS analysis after removal of the DH proteins confirmed the addition of water to (*Z*)-**16**, as established by the increase in mass of M+18 of each of the acyl-ACP products (Figure S19, Table S5). Finally, chiral GC-MS analysis established the exclusive formation of the derived methyl (2*R*,3*S*)-2-methyl-3-hydroxybutyrate (**7-Me**) (Figure S20). In the negative control, treatment of (*Z*)-**16** with NigDH1 did not result in the formation of detectable hydration product.

The above-described experiments establish conclusively that the dehydratase domains from the bongkrekic acid and oxazolomycin polyketide synthases, BonDH2 and OxaDH5, each catalyze the *syn* dehydration of (2*R*,3*S*)-2-methyl-3-hydroxyacyl-ACP substrates, which are exclusively generated by their respective paired BonKR2 and OxaKR5 domains, to give the corresponding (*Z*)-2-methylenoyl-ACP products. These findings constitute the first experimental demonstrations of the DH-catalyzed formation of a *Z*-trisubstituted double bond, in spite of a number of unsuccessful prior efforts, cited above, that have been directed toward this surprisingly elusive goal. Protein sequence alignments indicate that all of these dehydratases retain a conserved set of active site His and Asp residues but harbor no obvious DH sequence motifs that can be correlated with the *E*- or *Z*-configuration of their characteristic disubstituted or trisubstituted enoyl-ACP products (Figure S21).<sup>32</sup> All PKS DH-catalyzed dehydration and/or hydration reactions for which the stereochemistry has been determined involve a reversible *syn* elimination/addition of water,<sup>15–17</sup> in common with the established stereospecificity of the closely related FabA and FabZ dehydratase domains of *E. coli* fatty acid biosynthesis<sup>33, 34</sup> as well as the analogous action of the yeast fatty acid synthase.<sup>35</sup> The ultimate *E* or *Z* enoyl-ACP product geometry must reflect

important differences in the active site conformation of the bound 3-hydroxyacyl-ACP substrates that are not obviously correlated with any conserved amino acid sequence motifs.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


### Funding

This work was supported by a grant from the U. S. National Institutes of Health, GM022172, to D.E.C.


## References

1. Moebius N, Ross C, Scherlach K, Rohm B, Roth M, Hertweck C. *Chem Biol.* 2012; 19:1164–1174. [PubMed: 22999884]
2. Zhao C, Coughlin JM, Ju J, Zhu D, Wendt-Pienkowski E, Zhou X, Wang Z, Shen B, Deng Z. *J Biol Chem.* 2010; 285:20097–20108. [PubMed: 20406823]
3. Lewy DS, Gauss CM, Soenen DR, Boger DL. *Curr Med Chem.* 2002; 9:2005–2032. [PubMed: 12369868]
4. Kong R, Liu X, Su C, Ma C, Qiu R, Tang L. *Chem Biol.* 2013; 20:45–54. [PubMed: 23352138]
5. Shah DD, You YO, Cane DE. *J Am Chem Soc.* 2017; 139:14322–14330. [PubMed: 28902510]
6. Palaniappan N, Alhamadsheh MM, Reynolds KA. *J Am Chem Soc.* 2008; 130:12236–12237. [PubMed: 18714992]
7. Vergnolle O, Hahn F, Baerga-Ortiz A, Leadlay PF, Andexer JN. *Chembiochem.* 2011; 12:1011–1014. [PubMed: 21472957]
8. Olano C, Wilkinson B, Sanchez C, Moss SJ, Sheridan R, Math V, Weston AJ, Brana AF, Martin CJ, Oliynyk M, Mendez C, Leadlay PF, Salas JA. *Chem Biol.* 2004; 11:87–97. [PubMed: 15112998]
9. Moldenhauer J, Chen XH, Borriss R, Piel J. *Angew Chem Int Ed Engl.* 2007; 46:8195–8197. [PubMed: 17886826]
10. Butcher RA, Schroeder FC, Fischbach MA, Straight PD, Kolter R, Walsh CT, Clardy J. *Proc Natl Acad Sci U S A.* 2007; 104:1506–1509. [PubMed: 17234808]
11. Akey DL, Razelun JR, Tehranisa J, Sherman DH, Gerwick WH, Smith JL. *Structure.* 2010; 18:94–105. [PubMed: 20152156]
12. Fiers WD, Dodge GJ, Sherman DH, Smith JL, Aldrich CC. *J Am Chem Soc.* 2016; 138:16024–16036. [PubMed: 27960309]
13. Chen XH, Vater J, Piel J, Franke P, Scholz R, Schneider K, Koumoutsi A, Hitzeroth G, Grammel N, Strittmatter AW, Gottschalk G, Sussmuth RD, Borriss R. *J Bacteriol.* 2006; 188:4024–4036. [PubMed: 16707694]
14. Cheng YQ, Coughlin JM, Lim SK, Shen B. Chapter 8 Type I Polyketide Synthases That Require Discrete Acyltransferases. In *Complex Enzymes in Microbial Natural Product Biosynthesis, Part B: Polyketides, Aminocoumarins and Carbohydrates.* 2009:165–186.
15. Valenzano CR, You YO, Garg A, Keatinge-Clay A, Khosla C, Cane DE. *J Am Chem Soc.* 2010; 132:14697–14699. [PubMed: 20925342]
16. Guo X, Liu T, Valenzano CR, Deng Z, Cane DE. *J Am Chem Soc.* 2010; 132:14694–14696. [PubMed: 20925339]
17. Gay D, You YO, Keatinge-Clay A, Cane DE. *Biochemistry.* 2013; 52:8916–8928. [PubMed: 24274103]
18. Wu J, Zaleski TJ, Valenzano C, Khosla C, Cane DE. *J Am Chem Soc.* 2005; 127:17393–17404. [PubMed: 16332089]
19. Li Y, Dodge GJ, Fiers WD, Fecik RA, Smith JL, Aldrich CC. *J Am Chem Soc.* 2015; 137:7003–7006. [PubMed: 26027428]

20. Kandziora N, Andexer JN, Moss SJ, Wilkinson B, Leadlay PF, Hahn F. *Chem Sci*. 2014; 5:3563–3567.
21. Kallberg Y, Oppermann U, Jornvall H, Persson B. *Eur J Biochem*. 2002; 269:4409–4417. [PubMed: 12230552]
22. Kallberg Y, Oppermann U, Jornvall H, Persson B. *Protein Sci*. 2002; 11:636–641. [PubMed: 11847285]
23. Keatinge-Clay AT. *Chem Biol*. 2007; 14:898–908. [PubMed: 17719489]
24. Zheng J, Keatinge-Clay AT. *Med Chem Commun*. 2013; 4:34–40.
25. Reid R, Piagentini M, Rodriguez E, Ashley G, Viswanathan N, Carney J, Santi DV, Hutchinson CR, McDaniel R. *Biochemistry*. 2003; 42:72–79. [PubMed: 12515540]
26. Caffrey P. *ChemBioChem*. 2003; 4:654–657. [PubMed: 12851937]
27. Siskos AP, Baerga-Ortiz A, Bali S, Stein V, Mamdani H, Spitteller D, Popovic B, Spencer JB, Staunton J, Weissman KJ, Leadlay PF. *Chem Biol*. 2005; 12:1145–1153. [PubMed: 16242657]
28. Castonguay R, He W, Chen AY, Khosla C, Cane DE. *J Am Chem Soc*. 2007; 129:13758–13769. [PubMed: 17918944]
29. Xie X, Garg A, Khosla C, Cane DE. *J Am Chem Soc*. 2017; 139:3283–3292. [PubMed: 28157306]
30. Lu H, Tsai SC, Khosla C, Cane DE. *Biochemistry*. 2002; 41:12590–12597. [PubMed: 12379101]
31. Xie X, Garg A, Khosla C, Cane DE. *J Am Chem Soc*. 2017; 139:9507–9510. [PubMed: 28682630]
32. Keatinge-Clay A. *J Mol Biol*. 2008; 384:941–953. [PubMed: 18952099]
33. Schwab JM, Habib A, Klassen JB. *J Am Chem Soc*. 1986; 108:5304–5308.
34. Schwab JM, Henderson BS. *Chem Rev*. 1990; 90:1203–1245.
35. Sedgwick B, Morris C, French SJ. *J C S Chem Commun*. 1978:193–194.




**Figure 1.** Domain organization of the *trans*-AT polyketide synthase modules that generate (*Z*)-trisubstituted double bonds in bongkreikic acid (**1**) and oxazolomycin (**2**). The indicated methyl groups are introduced by *C*-methyl transferase (MT) domains.




**Figure 2.** Mega3.0 (<http://www.megasoftware.net>) sequence alignment of PKS ketoreductase domains that reduce 2-methyl-3-ketoacyl-ACP intermediates, showing the four different stereochemical classes of KR domains. Conserved K, S, and Y residues constitute the canonical active site catalytic triad of SDR proteins. The BaeKR9, BonKR2, DifKR6, and OxaKR5 domains lack the conserved sequence motifs diagnostic of established KR Types. PKS source: Amp, amphotericin; Ave, avermectin; Bae, bacillaene; Bon, bongkreic acid; bor, borrelidin; Con, concanamycin A; Dif, difficidin; Ery, erythromycin; Lan, lankamycin; Lip, lipomycin; Meg, megalomicin; Mei, meilingmycin; Nys, nystatin; Oxa, oxazolomycin; Pic, picromycin; Pla, pladienolide; Tyl, tylactone.





**Scheme 1.**  
Stereochemistry of *BonKR2*- and *OxaKR5*-Catalyzed Reduction of 2-Methyl-3-ketoacyl Thioesters.



**Scheme 2.**  
Stereochemistry of BonDH2- and OxaDH5-Catalyzed Dehydration/Hydration Reactions